K Y Park1,2, T Ozaki3, A Kostynskyy3, H Kortman3,4, A Hilario3, P Nicholson3, R Agid3, T Krings3, V M Pereira3. 1. From the Division of Neuroradiology (K.Y.P., T.O., A.K., H.K., A.H., P.N., R.A., T.K., V.M.P.), Joint Department of Medical Imaging, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada kypark78.md@gmail.com. 2. Department of Neurosurgery (K.Y.P.), Severance Stroke Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. 3. From the Division of Neuroradiology (K.Y.P., T.O., A.K., H.K., A.H., P.N., R.A., T.K., V.M.P.), Joint Department of Medical Imaging, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada. 4. Department of Radiology (H.K.), Elisabeth-TweeSteden Ziekenhuis St. Elisabeth Hospital, Tilburg, the Netherlands.
Abstract
BACKGROUND AND PURPOSE: Ticagrelor is a novel P2Y12 antagonist, and little is known about its efficacy and safety in the endovascular treatment of aneurysms. This study evaluated the efficacy and safety of ticagrelor versus clopidogrel for stent-assisted coiling or flow-diversion treatment in patients with unruptured cerebral aneurysms. MATERIALS AND METHODS: From November 2003 to February 2019, two hundred one patients (mean age, 57.5 years; 156 women) with 233 unruptured aneurysms underwent stent-assisted coiling or flow-diversion treatment. All patients received antiplatelet therapy of aspirin plus clopidogrel (clopidogrel group, 121 patients with 140 aneurysms) or aspirin plus ticagrelor (ticagrelor group, 80 patients with 93 aneurysms). The clinical and radiologic data in each group were retrospectively reviewed and compared. RESULTS: Two hundred thirty-six procedures were performed, including stent-assisted coiling (n = 101) and flow diversion (n = 135). At 90 days, the primary outcome-a composite of any stroke and death-occurred in 9.9% of the clopidogrel group and 8.6% of the ticagrelor group (P = .822). Ischemic stroke occurred in 10 (7.0%) of the clopidogrel group and 7 (7.5%) of the ticagrelor group (P > .999). Disabling stroke occurred in 4 (2.8%) in the clopidogrel group and in 4 (4.3%) in the ticagrelor group (P = .716). Ninety-day death occurred in 3 (2.1%) in the clopidogrel group and 1 (1.1%) in the ticagrelor group (P > .999). Any bleeding at 90 days occurred in 13 (9.2%) in the clopidogrel group and 6 (6.5%) in the ticagrelor group (P = .479). CONCLUSIONS: Ticagrelor appears to be as effective and safe as clopidogrel in stent-assisted coiling or flow-diversion treatment for unruptured cerebral aneurysms.
BACKGROUND AND PURPOSE: Ticagrelor is a novel P2Y12 antagonist, and little is known about its efficacy and safety in the endovascular treatment of aneurysms. This study evaluated the efficacy and safety of ticagrelor versus clopidogrel for stent-assisted coiling or flow-diversion treatment in patients with unruptured cerebral aneurysms. MATERIALS AND METHODS: From November 2003 to February 2019, two hundred one patients (mean age, 57.5 years; 156 women) with 233 unruptured aneurysms underwent stent-assisted coiling or flow-diversion treatment. All patients received antiplatelet therapy of aspirin plus clopidogrel (clopidogrel group, 121 patients with 140 aneurysms) or aspirin plus ticagrelor (ticagrelor group, 80 patients with 93 aneurysms). The clinical and radiologic data in each group were retrospectively reviewed and compared. RESULTS: Two hundred thirty-six procedures were performed, including stent-assisted coiling (n = 101) and flow diversion (n = 135). At 90 days, the primary outcome-a composite of any stroke and death-occurred in 9.9% of the clopidogrel group and 8.6% of the ticagrelor group (P = .822). Ischemic stroke occurred in 10 (7.0%) of the clopidogrel group and 7 (7.5%) of the ticagrelor group (P > .999). Disabling stroke occurred in 4 (2.8%) in the clopidogrel group and in 4 (4.3%) in the ticagrelor group (P = .716). Ninety-day death occurred in 3 (2.1%) in the clopidogrel group and 1 (1.1%) in the ticagrelor group (P > .999). Any bleeding at 90 days occurred in 13 (9.2%) in the clopidogrel group and 6 (6.5%) in the ticagrelor group (P = .479). CONCLUSIONS: Ticagrelor appears to be as effective and safe as clopidogrel in stent-assisted coiling or flow-diversion treatment for unruptured cerebral aneurysms.
Authors: L Ian Taylor; James C Dickerson; Robert J Dambrino; M Yashar S Kalani; Philipp Taussky; Chad W Washington; Min S Park Journal: Neurosurg Focus Date: 2017-06 Impact factor: 4.047
Authors: Kartik Dev Bhatia; Hans Kortman; Emanuele Orru; Jesse M Klostranec; Vitor M Pereira; Timo Krings Journal: J Neurointerv Surg Date: 2019-05-30 Impact factor: 5.836
Authors: Emanuele Orru; Henry Rice; Laetitia De Villiers; Jesse M Klostranec; Ajay K Wakhloo; Alexander L Coon; Ivan Radovanovic; Hans Kortman; Kartik Dev Bhatia; Timo Krings; Vitor M Pereira Journal: J Neurointerv Surg Date: 2020-02-12 Impact factor: 5.836
Authors: Pierre Amarenco; Gregory W Albers; Hans Denison; J Donald Easton; Scott R Evans; Peter Held; Michael D Hill; Jenny Jonasson; Scott E Kasner; Per Ladenvall; Kazuo Minematsu; Carlos A Molina; Yongjun Wang; K S Lawrence Wong; S Claiborne Johnston Journal: Lancet Neurol Date: 2017-02-23 Impact factor: 44.182
Authors: Evan Luther; David J McCarthy; Marie-Christine Brunet; Samir Sur; Stephanie H Chen; Dallas Sheinberg; David Hasan; Pascal Jabbour; Dileep R Yavagal; Eric C Peterson; Robert M Starke Journal: J Neurointerv Surg Date: 2020-01-20 Impact factor: 5.836
Authors: Rachel C Orme; William A E Parker; Mark R Thomas; Heather M Judge; Kathleen Baster; Wael Sumaya; Kenneth P Morgan; Hannah C McMellon; James D Richardson; Ever D Grech; Nigel M Wheeldon; Ian R Hall; Javaid Iqbal; David Barmby; Julian P Gunn; Robert F Storey Journal: Circulation Date: 2018-06-21 Impact factor: 29.690
Authors: D P O Kaiser; G Boulouis; S Soize; V Maus; S Fischer; D Lobsien; J Klisch; H Styczen; C Deuschl; N Abdullayev; C Kabbasch; A Jamous; D Behme; K Janot; G Bellanger; C Cognard; L Pierot; M Gawlitza Journal: AJNR Am J Neuroradiol Date: 2022-06-23 Impact factor: 4.966